Correlations between serum homocysteine levels and RoPE score in patients with patent foramen ovale

Zuin, Marco; Rigatelli, Gianluca; Rigatelli, Alberto; Ronco, Federico; Conte, Luca; Roncon, Loris; Mazza, Alberto

doi:10.1007/s00380-019-01528-5

Cited by 3 publications

(3 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The 10-point risk of paradoxical embolism (RoPE) score is an index that was created to stratify cryptogenic stroke patients with PFO by their likelihood that the stroke was related to their PFO [ 44 ]. Zuin et al found a direct correlation between serum homocysteine levels and the RopE score in a sample of 244 PFO patients [ 45 ]. A receiver operating curve identified the optimal cutoff value of 19.5 μg/dL for homocysteinemia as a predictor of a high RoPE score > 7 in the group of patients with PFO that underwent a closure procedure (AUC 0.90, 95% CI 0.81–0.94, p < 0.0001).…”

Section: Patent Foramen Ovalementioning

confidence: 99%

“…A receiver operating curve identified the optimal cutoff value of 19.5 μg/dL for homocysteinemia as a predictor of a high RoPE score > 7 in the group of patients with PFO that underwent a closure procedure (AUC 0.90, 95% CI 0.81–0.94, p < 0.0001). Multivariate logistic regression analysis demonstrated that a homocysteine serum level ≥ 19.5 μg/dL predicted a RoPE score > 7 (OR 3.21, 95% CI 2.82–3.26, p < 0.0001) in closed patients independently from the presence of a permanent right-to-left shunt (OR 2.28, 95% CI 2.01–2.43, p = 0.001) and atrial septal aneurysm (OR 3.04, 95% CI 2.64–3.51, p < 0.0001) [ 45 ].…”

Section: Patent Foramen Ovalementioning

confidence: 99%

See 1 more Smart Citation

Update on Biomarkers Associated to Cardioembolic Stroke: A Narrative Review

Fonseca

Coelho

2021

Life

View full text Add to dashboard Cite

Background: In the last years, several studies were conducted that evaluated biomarkers that could be helpful for cardioembolic stroke diagnosis, prognosis, and the determination of risk of stroke recurrence. Methods: We performed a narrative review of the main studies that evaluated biomarkers related to specific cardioembolic causes: atrial fibrillation, patent foramen ovale, atrial cardiomyopathy, and left ventricular wall motion abnormalities. Results: BNP and NT-proBNP are, among all biomarkers of cardioembolic stroke, the ones that have the highest amount of evidence for their use. NT-proBNP is currently used for the selection of patients that will be included in clinical trials that aim to evaluate the use of anticoagulation in patients suspected of having a cardioembolic stroke and for the selection of patients to undergo cardiac monitoring. NT-proBNP has also been incorporated in tools used to predict the risk of stroke recurrence (ABC-stroke score). Conclusions: NT-proBNP and BNP continue to be the biomarkers most widely studied in the context of cardioembolic stroke. The possibility of using other biomarkers in clinical practice is still distant, mainly because of the low methodological quality of the studies in which they were evaluated. Both internal and external validation studies are rarely performed for most biomarkers.

show abstract

Section: Patent Foramen Ovalementioning

confidence: 99%

Section: Patent Foramen Ovalementioning

confidence: 99%

Update on Biomarkers Associated to Cardioembolic Stroke: A Narrative Review

Fonseca

Coelho

2021

Life

View full text Add to dashboard Cite

show abstract

“…In addition to echocardiographic diagnostic, and clinical score assessing ischemic stroke susceptibility in patients with PFO, few blood biomarkers have been proposed to improve risk estimation of ischemic stroke recurrence. Blood biomarkers, such as high levels of D-Dimer [111] and homocysteine [112], and low l -arginine/asymmetric dimethylarginine ( l -Arg/ADMA) ratio [113] are associated with higher likelihood of ischemic stroke recurrency in patients with PFO. These biomarkers may aid the selection of patients for interventional PFO-occlusion.…”

Section: Etiological Blood Biomarkersmentioning

confidence: 99%

Precision medicine in secondary prevention of ischemic stroke: how may blood-based biomarkers help in clinical routine? An expert opinion

Bicciato

Arnold

Gebhardt

et al. 2021

Current Opinion in Neurology

View full text Add to dashboard Cite

Purpose of reviewOne in eight patients unfortunately suffers a new stroke within 5 years of their first stroke, even today. Research in precision medicine could lead to a more individualized treatment allocation, possibly achieving lower recurrence rates of ischemic stroke. In this narrative review, we aim to discuss potential clinical implementation of several promising candidate blood biomarkers. Recent findingsWe discuss specifically some promising blood-based biomarkers, which may improve the identification of underlying causes as well as risk stratification of patients according to their specific cerebrovascular risk factor pattern. SummaryMultimodal profiling of ischemic stroke patients by means of blood biomarkers, in addition to established clinical and neuroradiological data, may allow in the future a refinement of decision algorithms for treatment allocation in secondary ischemic stroke prevention.

show abstract

Thrombus straddling a patent foramen ovale: Also a myocardial infarction matter?

Zuin

Rigatelli

2021

International Journal of Cardiology

View full text Add to dashboard Cite

Correlations between serum homocysteine levels and RoPE score in patients with patent foramen ovale

Cited by 3 publications

References 18 publications

Update on Biomarkers Associated to Cardioembolic Stroke: A Narrative Review

Update on Biomarkers Associated to Cardioembolic Stroke: A Narrative Review

Precision medicine in secondary prevention of ischemic stroke: how may blood-based biomarkers help in clinical routine? An expert opinion

Thrombus straddling a patent foramen ovale: Also a myocardial infarction matter?

Contact Info

Product

Resources

About